By Steven D. Vold, MD
By Leonard K. Seibold, MD; Malik Y. Kahook, MD; and Jeffrey R. SooHoo, MD
BENCH TO BEDSIDE
Laboratory studies may help us better understand our clinical dilemmas.
By Dan Eisenberg, MD
Select research findings presented this year.
By Sze H. Wong, MD, and Albert S. Khouri, MD
By Ahmad A. Aref, MD; Kavitha R. Sivaramen, MD; and Ali R. Djalilian, MD
RESIDENTS AND FELLOWS
By Linda Huang, MD
COVER FOCUS: Ocular Surface Disease
The preoperative planning process is more complex and requires careful attention to the unique issues at play.
By Tony Realini, MD, MPH
Many systemic and topical drugs can cause or worsen dry eye disease.
By Sarah Marshall, PhD, and Robert Noecker, MD, MBA
The role of point-of-care testing in dry eye disease and glaucoma management.
By Leslie E. O’Dell, OD
The principles and clinical significance of various technologies.
By Alice T. Epitropoulos, MD
This procedure improves the health of the meibomian glands.
By Rolando Toyos, MD
New technologies provide more information and better outcomes than ever before.
By Sheri Rowen, MD
By Paul S. Koch, MD, and Thandeka Myeni, MD, MPH
A device in clinical study could lead to new understanding of dry eye as a neuronal disease.
By John Berdahl, MD
The merging of two mindsets requires skill, versatility, and sensitivity.
By Wolfgang Riha, MD
Adalimumab, a rheumatology drug, offers hope to patients with this damaging inflammatory eye disease.